MeiraGTx is a biotechnology company that focuses on developing gene therapies to treat inherited and acquired genetic disorders.
MeiraGTx has raised $100.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in April 2026.
MeiraGTx's investors include Sanofi, Perceptive Advisors, ATW Partners, AlbionVC, UCL Technology Fund.
MeiraGTx is headquartered in New York, United States.
MeiraGTx is a biotechnology company that focuses on developing gene therapies to treat inherited and acquired genetic disorders.
MeiraGTx is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"MeiraGTx — Funding & Investors." VCBacked, April 16, 2026, https://www.vcbacked.co/company/meiragtx. Accessed September 30, 2026.
VCBacked. (2026). MeiraGTx — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/meiragtx
{{cite web |title=MeiraGTx — Funding & Investors |url=https://www.vcbacked.co/company/meiragtx |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated